Table 2.

Clinical trials of colchicine and IL-1 blockers in AMI and heart failure

Disease	Clinical Trial Name	Study Design and Drug Regimen	Main Finding(s)	Reference(s)
ST-segment elevation AMI	Anti-Inflammatory Treatment With Colchicine in AMI	Randomization 1:1	Reduced infarct size (cardiac magnetic resonance and cardiac biomarkers); reduced peak CRP	28
		Colchicine or placebo
(n = 151)		Loading dose of 2 mg (1.5 mg initially followed by 0.5 mg 1 h later) and continuing with 0.5 mg twice daily, or placebo, for 5 days
ST-segment elevation AMI	VCU-ART	Randomization 1:1	Reduced peak CRP; trend toward reduced incidence of heart failure at 3 mo and at long-term followup with anakinra	2, 3, 6
(n = 10)	VCU-ART2	Anakinra or placebo
(n = 30)		Anakinra 100 mg once daily for 14 days
Non-ST-segment elevation AMI	MRC-ILA Heart Study	Randomization 1:1	Reduced peak CRP; no differences in major adverse cardiac events at 30 days and 3 mo, but more events after 6 mo in the anakinra-treated group	98
(n = 182)		Anakinra or placebo
		Anakinra 100 mg once daily for 14 days

AMI, acute myocardial infarction; CRP, C-reactive protein.